SouthState Corp Acquires 1,025 Shares of AstraZeneca PLC (NASDAQ:AZN)

SouthState Corp grew its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 1.6% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 64,747 shares of the company’s stock after buying an additional 1,025 shares during the period. SouthState Corp’s holdings in AstraZeneca were worth $5,044,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Stratos Wealth Advisors LLC grew its stake in shares of AstraZeneca by 2.0% in the 3rd quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock valued at $522,000 after buying an additional 133 shares during the period. Bruce G. Allen Investments LLC grew its stake in AstraZeneca by 19.1% in the second quarter. Bruce G. Allen Investments LLC now owns 860 shares of the company’s stock valued at $67,000 after acquiring an additional 138 shares during the period. Carnegie Investment Counsel increased its holdings in shares of AstraZeneca by 0.8% during the second quarter. Carnegie Investment Counsel now owns 17,269 shares of the company’s stock valued at $1,347,000 after acquiring an additional 138 shares in the last quarter. Crumly & Associates Inc. raised its position in shares of AstraZeneca by 2.2% during the third quarter. Crumly & Associates Inc. now owns 6,644 shares of the company’s stock worth $518,000 after purchasing an additional 143 shares during the period. Finally, CANADA LIFE ASSURANCE Co grew its position in AstraZeneca by 40.6% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock valued at $34,000 after purchasing an additional 146 shares during the period. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Price Performance

Shares of NASDAQ:AZN opened at $63.39 on Tuesday. The company has a market capitalization of $196.55 billion, a P/E ratio of 30.33, a price-to-earnings-growth ratio of 1.17 and a beta of 0.47. The company’s 50-day moving average is $74.68 and its 200 day moving average is $78.15. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm had revenue of $13.57 billion for the quarter, compared to analysts’ expectations of $13.08 billion. During the same period in the previous year, the company earned $0.87 earnings per share. The company’s quarterly revenue was up 18.0% on a year-over-year basis. On average, equities research analysts forecast that AstraZeneca PLC will post 4.07 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on AZN shares. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. TD Cowen upped their target price on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Finally, Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.